Skip to main content

Table 2 Various bacteria abundance in patients with CRC

From: Gut microbiota modulation: a tool for the management of colorectal cancer

Bacteria Detection method Sample (n) Positive percentage Sample type Affiliation Refs.
H. pylori Multiplex serology 4063 41% Serum USA [20]
H. pylori ELISA 1712 46.1% Serum Germany [21]
H. pylori Multiplex serology 1488 90% Serum Spain [22]
F. nucleatum qPCR 160 66.9% FFPE tissue Korea [23]
F. nucleatum qPCR 100 75% Frozen tissue Japan [24]
F. nucleatum qPCR 39 82.1% Tissue Korea [25]
E. coli PCR 31 90% Tissue Germany [26]
E. coli PCR 48 16.7% Tissue Malaysia [27]
E. coli PCR 48 83% Tissue Iran [28]
B. fragilis PCR 49 88.5% Mucosal tissue USA [29]
B. fragilis PCpR 60 58.3% Stool Iran [30]
P. anaerobius qPCR 154 NA Mucosa/Stool China [31]
P. gingivalis qPCR 31 32.2% Tissue China [32]
P. gingivalis PCR 71 76% Saliva Turkey [33]
E. faecalis PCR 20 NA Stool India [34]
E. faecalis qPCR 9 22.2% Stool Italy [35]
S. gallolyticus qPCR 148 74% Tissue USA [36]
S. gallolyticus qPCR 190 3.2% Tissue Spain [37]
  1. ELISA enzyme-linked immunosorbent assay, qPCR quantitative real‐time polymerase chain reaction, FFPE formalin‐fixed paraffin‐embedded